NeuroPace (NASDAQ:NPCE) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of NeuroPace (NASDAQ:NPCE – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other brokerages also recently commented on NPCE. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NeuroPace in a research note on Tuesday, September 15th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of NeuroPace in a research note on Wednesday, July 29th. Raymond James Financial set a $21.00 target price on NeuroPace in a research note on Tuesday, September 15th. Weiss Ratings downgraded NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. Finally, Guggenheim restated a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $13.11.

View Our Latest Report on NPCE

NeuroPace Trading Up 5.4%

Shares of NPCE opened at $7.97 on Friday. The stock has a market capitalization of $273.53 million, a P/E ratio of -14.23 and a beta of 1.98. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. The firm has a fifty day simple moving average of $13.07 and a two-hundred day simple moving average of $14.71. NeuroPace has a twelve month low of $5.46 and a twelve month high of $19.60.

Institutional Investors Weigh In On NeuroPace

A number of large investors have recently modified their holdings of NPCE. Soleus Capital Management L.P. increased its position in shares of NeuroPace by 10.5% during the third quarter. Soleus Capital Management L.P. now owns 3,218,000 shares of the company’s stock valued at $44,280,000 after buying an additional 306,878 shares during the period. First Light Asset Management LLC lifted its holdings in NeuroPace by 16.3% in the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after buying an additional 401,201 shares during the period. BlackRock Inc. bought a new stake in NeuroPace during the 2nd quarter valued at approximately $39,369,000. Deutsche Bank AG bought a new stake in NeuroPace during the 2nd quarter valued at approximately $14,919,000. Finally, Algert Global LLC boosted its position in NeuroPace by 2.9% during the 2nd quarter. Algert Global LLC now owns 184,774 shares of the company’s stock valued at $2,936,000 after acquiring an additional 5,218 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

Further Reading

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.